All you need to know about Dengue vaccine TAK-003

Sushmita Panda

May 15, 2024

The World Health Organization (WHO) on Wednesday announced that it has prequalified new dengue vaccine.

According to WHO, the vaccine, developed by Takeda Pharmaceuticals, received prequalification on 10 May 2024.

The vaccine, TAK-003, is the second dengue vaccine to be prequalified by WHO.

WHO recommends the use of TAK-003 in children aged 6–16 years in settings with high dengue burden and transmission intensity.

The vaccine should be administered in a 2-dose schedule with a 3-month interval between doses.

The WHO prequalification list also includes CYD-TDV vaccine against dengue developed by Sanofi Pasteur.

TAK-003 vaccine is a live-attenuated vaccine containing weakened versions of the four serotypes of the virus that cause dengue.

The UK, Brazil, Argentina, Indonesia and Thailand have also approved TAK-003.